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Abstract
Background: Clinical practice guidelines consider the use of antidepressants as one of the standard treatments for
anxiety disorders, due to the significant improvements obtained in quality of life and functional disability. In
addition, in patients who have not achieved a favorable response after 3 months of psychotherapy, antidepressants
are recommended as part of a combined treatment approach. This combination with psychotropic drugs and
psychotherapy appears to be indicated from baseline in patients with moderate, severe or recurrent depression. In
the last decade, antidepressant prescription rates in general practice have increased between 4 and 10 times.
Depression presents high rates of relapse and recurrence. Treatment is often interrupted prematurely, leading to
increases in both relapse rates and health care costs. Few studies have analysed the chronic use of antidepressant
drugs and long-term adherence. Objective: To evaluate compliance with antidepressant treatment between 2003
and 2011 and to explore the associated factors.
Methods: Retrospective cohort study of antidepressant dispensing. Setting: Health Region of Lleida between 2003
and 2011. Participants: Patients with chronic prescription of antidepressants (ATC code NO6A) during 2003 were
followed up until December 2011. The sample comprised 3684 subjects. Main measures: The compliance rate was
calculated on the basis of the number of units withdrawn from the pharmacy and the theoretical number of units
required according to the scheduled duration of treatment: compliance was defined in cases with scores greater
than or equal to 80 %.
Results: 12.5 % of patients received chronic antidepressant treatment for at least 4 years. Mean age was 54 years,
and 73.2 % of patients were female. Almost a third (32.4 %) presented anxiety disorders and 26.5 % mood disorders.
The overall compliance rate was 22 % (28 % in patients with depression, and 21 % in patients with anxiety).
According to gender, compliance rates were 21.4 % for males and 22.4 % for females. Compliance was more likely
in patients with polypharmacy.
Conclusions: One in 4 patients complied with treatment. Factors associated with better compliance were
polypharmacy and diagnosis of depressive or mixed anxiety-depressive disorder.
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Background
After cardiovascular diseases, mental illness is the
second leading cause of disease burden in economically
developed countries, and one of the categories that most
reduces the number of years of disease-free life [1]. Al-
though the prevalence of depression has not increased
over time [2], depressive disorders account for 40.5 % of
the disability-adjusted life years caused by mental illness
[3]. The global current prevalence of anxiety disorders is
7.3 %, ranging from 5.3 % in African cultures to 10.4 %
in Euro/Anglo cultures [4]. The European ESEMeD
epidemiological study found a lifetime prevalence of
mood disorders of 14.7 % [5]. In Spain the prevalence of
depressive episodes has been reported to be 10.5 %,
making it the most common mental disorder [6].
Clinical practice guidelines vary from country to
country. The NICE guidelines recommend psychological
interventions as the first line of therapy and favour
pharmacological treatment only as a later additional step
in the case of non-response to psychotherapy. The use
of antidepressants is one of the standard treatments for
anxiety disorders, due to the significant improvements
obtained in quality of life and in functional disability.
Routine use of benzodiazepines should be avoided be-
cause they are associated with tolerance and depend-
ence, and antipsychotics are associated with a number of
adverse effects [7].
In patients with depression who have not achieved a
favourable response after three months of psychother-
apy, antidepressants are recommended as part of a com-
bined treatment approach. This combination with
psychotropic drugs and psychotherapy appears to be in-
dicated from baseline in patients with moderate, severe
or recurrent depression [8].
Depression presents high rates of relapse and recur-
rence [9]. After the first episode, the 2-year recurrence
rate is 40 %, and after two episodes, the risk of recur-
rence at 5 years is 75 %. Furthermore, 10-30 % of pa-
tients do not recover completely; their symptoms persist,
or they develop dysthymia [10]. In the last decade
antidepressant prescription rates in general practice have
increased between 4 and 10 times [11, 12]. The appro-
priateness of long-term treatment with antidepressants
is currently being debated [13], although the rates of
treatment compliance in chronic follow-up is unknown.
Treatment is often interrupted prematurely, leading to
increases in both relapse rates and health care costs [14];
some research shows that 40 % of patients discontinue
the use of antidepressant medication during the first
3 months [15].
Few studies have analysed the relation between
chronic use of antidepressant drugs and long-term com-
pliance. The present study aimed to assess compliance
with antidepressant treatment in a Spanish health region




A retrospective cohort study of the dispensing of antide-
pressants. Data were taken from prescriptions made in
the Lleida Health Region between January 1, 2002 and
December 31, 2011.
Data source
The data were obtained from the database of the
Catalan Health Service for the dispensing of prescrip-
tion drugs in pharmacies. In Catalonia, since the
presentation of the health card is required to obtain
medication with a Social Security prescription, users
can be unambiguously identified. The prescription of
antidepressants corresponds to group NO6A of the
Anatomical Therapeutic Chemical classification in use
in Spain [16] (Table 1).
Affiliation data (date of birth and gender), administra-
tive status (includes death / change of address to another
region) and medical diagnoses of anxiety and depression
were extracted from the primary care information systems,
in accordance with the International Classification of Dis-
eases Version 10 (Diagnosis of anxiety: ICD-10 F40-F43;
Diagnosis of depression: ICD-10: F30-F39).
Variables
The variables studied were: age at beginning of study, gen-
der, units of antidepressants withdrawn from the phar-
macy, polypharmacy, and clinical diagnosis justifying the
prescription. A patient’s level of polypharmacy was defined
as the number of different active principles prescribed
monthly during the study period [17, 18]. Polypharmacy
was divided into 4 groups, as follows (low: use of <2 drugs,
normal: concomitant use of 2 to 2.7 drugs; moderate: 2.7
to 4.3 drugs, and high: > 4.3 drugs).
Selection of the cohort
Patients with a new prescription of an antidepressant
during 2003 and still receiving treatment after January
2008 were followed up until December 2011. The sam-
ple comprised 3684 subjects (26.8 % males and 73.2 %
females, mean age of 53.7 years (SD = 17.8).
Exclusion criteria
Patients who were dispensed antidepressants in 2002 or
had received amitriptyline for neuropathic pain were ex-
cluded from the study (n = 317).
Definition of compliance with treatment
Compliance with treatment was defined based on the
units of medication dispensed during the treatment
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period. Treatment duration was calculated for each pa-
tient on the basis of the number of months from the first
dispensing in 2003 to the last one before December 31,
2011. For each antidepressant, the number of units per
month needed by the patient was considered according
to the recommended daily dose defined by the WHO’s
Centre for Drugs Statistics Methodology [19]. The com-
pliance rate was thus calculated from the number of
units dispensed at the pharmacy and the number of
units theoretically required for the duration of episode.
By consensus, compliance rates of 80 % until the end of
treatment were considered adequate. A duration of at
least six months of antidepressant treatment was also re-
quired [20]. Treatment was defined as chronic when a
patient had received prescriptions on two or more occa-
sions during the period.
Statistical analysis
A descriptive analysis was performed of the cohort con-
sidering frequencies and percentages. The compliance
rate was estimated with a confidence interval of 95 %
using normal approximation. To determine its possible
association with other variables, the compliance rate was
described and the Chi-square significance test was per-
formed. Adjusted odds ratios (OR) of compliance with
treatment were estimated by multivariate logistic regres-
sion models. The complete model and a second model
with variables that showed statistical significance, two
logistic models (Enter method) were adjusted. The
Hosmer-Lemeshow test and area under the curve ROC
(AUC) were computed to evaluate the performance of
the multivariable models. P values less than 0.05 were
considered statistically significant”.
Results
During 2003, 29,517 individuals (8.6 % of the total regis-
tered population) were dispensed antidepressants in
pharmacies in the Lleida Health Region. Of the patients
who started antidepressant treatment in 2003, 12.5 %
were still receiving chronic treatment after 4 years. The
mean age of these patients was 54 years (SD: 17.82), and
73.2 % were women. In 2003, the general population in
the Health Region comprised 309,786 inhabitants:
48.2 % were women and the mean age was 42 years
(SD:23.9).
Anxiety disorders accounted for 25 %, mood disorders
19 %, mixed disorders 7 %, and in 49 % of cases no diag-
nosis was recorded.
The most frequently prescribed drug during the
early period (years 2003–2008) was paroxetine
followed by fluoxetine and sertraline. In the later
period (2008–2011) paroxetine remained the most fre-
quently prescribed, followed by escitalopram and then
venlafaxine third (Table 3).
As regards the number of different drugs prescribed,
68.6 % of patients had received treatment with 1 or 2 an-
tidepressants; 17.3 % with three, 7.8 % with four 4 %
with five, and the remaining 2.3 % up to thirteen differ-
ent antidepressant drugs.
The overall compliance was 22 % (95 % CI: 20.8 to
23.8 %). There were no statistically significant differences
between genders: compliance rates were 21.1 % (n = 211)
in males and 22.4 % (n = 605) in females. Compliance in-
creased with age, rising to 26.6 % in the over-65 age
group (n = 320). As regards polypharmacy, increasing
the number of drugs also improved the compliance rate.
Patients diagnosed with depression had a compliance
rate of 28 % while in those diagnosed with anxiety the
rate was 21 % (Table 2).
At multivariate level, the factors associated with compli-
ance were high levels of polypharmacy (>4.3), diagnosis of




ATC Description N° (%) N° (%)
Amitriptyline 594 (16.12) 429 (11.64)
Clomipramine 324 (8.79) 215 (5.84)
Lofepramine 1 (0.03) 0 (0.00)
Mianserin 115 (3.12) 71 (1.93)
Oxitriptan 9 (0.24) 1 (0.03)
Imipramine 27 (0.73) 26 (0.71)
Minaprine 1 (0.03) 0 (0.00)
Nortriptyline 18 (0.49) 12 (0.33)
Tranylcypromine 2 (0.05) 0 (0.00)
Trazodone 124 (3.37) 144 (3.91)
Trimipramine 2 (0.05) 2 (0.05)
Fluoxetine 1173 (31.84) 529 (14.36)
Maprotiline 101 (2.74) 47 (1.28)
Doxepin 3 (0.08) 4 (0.11)
Fluvoxamine 96 (2.61) 36 (0.98)
Moclobemide 1 (0.03) 0 (0.00)
Venlafaxine 687 (18.65) 538 (14.60)
Sertraline 861 (23.37) 463 (12.57)
Dosulepin 3 (0.08) 0 (0.00)
Reboxetine 68 (1.85) 48 (1.30)
Mirtazapine 312 (8.47) 293 (7.95)
Bupropion 0 (0.00) 90 (2.44)
Citalopram 972 (26.38) 814 (22.10)
Paroxetine 1633 (44.33) 950 (25.79)
Escitalopram 740 (20.09) 984 (26.71)
Duloxetine 203 (5.51) 402 (10.91)
Agomelatine 0 (0.00) 88 (2.39)
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depressive or mixed disorder, and consumption of clomip-
ramine, mirtazapine, maprotiline, or venlafaxine inde-
pendently of gender and age. Furthermore, compliance
with paroxetine and trazodone was lower after adjusting
for age, gender and drugs dispensed (Table 3).
Discussion
In 2003, a total of 29,517 (8.6 %) individuals were dis-
pensed at least one antidepressant unit from pharmacies
in the Lleida Health Region. Of the patients who started
treatment with antidepressants in 2003, 12.5 % remained
in treatment after 4 years. The mean age of patients was
54 years (SD: 17.82).
According to some reports, one-third of patients with
depression present episodes or symptoms for more than
2 years [21]. Other patients present recurrences and re-
quire chronic medication.
In our population, anxiety disorders accounted for
25 %, mood disorders 19 %, mixed disorder in 7 %, and
in 49 % no diagnosis was recorded. The descriptive
Table 2 Compliance with treatment stratified according to different variables
Compliance 95 % CI para %
Variable N n (%) (lower-upper) p value
Global 3684 816 (22.1) (20.8–23.5)
Gender
Male 988 211 (21.4) (18.7–24.0) 0.483
Female 2696 605 (22.4) (20.8–24.0)
Age group
Under 35 582 85 (14.6) (11.7–17.5) <0.001(*)
35–64 1901 411 (21.6) (19.7–23.5)
Over 65 1201 320 (26.6) (24.1–29.2)
Polypharmacy
=<2 826 59 (7.1) (5.4–8.9) <0.001(*)
2–2.6 822 123 (15.0) (12.5–17.5)
2.7–4.3 1057 276 (26.1) (23.4–28.8)
>4.3 979 358 (36.6) (33.5–39.6)
Diagnosis recorded
None 1785 351 (19.7) (17.8–21.5) <0.001(*)
Only anxiety 923 194 (21.0) (18.3–23.7)
Only depression 704 197 (28.0) (24.6–31.4)
Both 272 74 (27.2) (21.8–32.6)
Drug dispenseda
Amitriptyline 787 167 (21.2) (18.3–24.1) 0.479
Paroxetine 1880 332 (17.7) (15.9–19.4) <0.001(*)
Fluoxetine 1324 323 (24.4) (22.0–26.8) 0.014(*)
Citalopram 1363 318 (23.3) (21.0–25.6) 0.186
Sertraline 1024 266 (26.0) (23.2–28.7) 0.001(*)
Venlafaxine 932 309 (33.2) (30.1–36.2) <0.001(*)
Clomipramine 414 142 (34.3) (29.6–39.0) <0.001(*)
Mirtazapine 492 153 (31.1) (26.9–35.3) <0.001(*)
Trazodone 230 45 (19.6) (14.3–24.8) 0.33
Maprotiline 122 44 (36.1) (27.4–44.8) <0.001(*)
Imipramine 42 16 (38.1) (23.1–53.1) 0.012(*)
Nortriptyline 25 10 (40.0) (20.4–59.6) 0.031(*)
Fluvoxamine 118 39 (33.1) (24.4–41.7) 0.004(*)
*Significance using chi-squared test: p-value <0.05
aSome of the active principles were not considered because patient numbers were insufficient
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approach based on the diagnostic criteria of the CIE-10
[22] and the DSM-IV [23] has improved the identifica-
tion and treatment of mental disorders worldwide. How-
ever, even the creators of these systems recognize that
their main achievement has been to improve diagnostic
accuracy [24]; there is growing concern among experts
that the clinical utility these diagnostic criteria may be
seriously limited [25]. Several major problems have been
highlighted in the literature. First, a high proportion of
diagnoses of mental disorders are recorded as “unspeci-
fied” (the term used in ICD) or “not specified elsewhere”
(the corresponding term in the DSM). This suggests that
health professionals find the current categories difficult
to use or imprecise for describing their patients, or do
not find the nuances introduced by the diagnostic sub-
types useful in their clinical practice. Second, a high pro-
portion of people with mental health problems meet the
criteria for two or more disorders [26].
Table 3 Logistic regression models of the likelihood of better compliance with treatment
Model 1a Model 2b
Variable 95 % CI for OR 95 % CI for OR
Category OR (lower -upper) p-value OR (lower-upper) p-value
Sex
Female 1.04 (0.85–1.26) 0.721
Polypharmacy
=<2 (Ref.) <0.001 <0.001
2–2.6 2.11 (1.51–2.96) <0.001 2.10 (1.51–2.93) <0.001
2.7–4.3 4.67 (3.39–6.41) <0.001 4.48 (3.30–6.10) <0.001
>4.3 8.85 (6.33–12.35) <0.001 8.20 (6.02–11.11) <0.001
Age group
Under 35 (Ref.) 0.389
35–64 1.00 (0.75–1.33) 0.991
Over 65 0.87 (0.63–1.20) 0.392
Diagnosis recorded
None (Ref.) <0.001 <0.001
Only anxiety 1.41 (1.13–1.75) 0.002 1.45 (1.17–1.80) <0.001
Only depression 1.58 (1.26–1.97) <0.001 1.63 (1.31–2.03) <0.001
Ambos 1.74 (1.25–2.42) 0.001 1.84 (1.33–2.54) <0.001
Drug dispensed
Amitriptyline 0.81 (0.66–1.00) 0.047
Paroxetine 0.57 (0.48–0.68) <0.001 0.57 (0.48–0.68) <0.001
Fluoxetine 1.09 (0.91–1.30) 0.335
Citalopram 1.05 (0.88–1.25) 0.604
Sertraline 1.11 (0.93–1.34) 0.256
Venlafaxine 1.92 (1.59–2.30) <0.001 1.99 (1.66–2.39) <0.001
Clomipramine 1.78 (1.40–2.27) <0.001 1.80 (1.41–2.28) <0.001
Mirtazapine 1.39 (1.10–1.75) 0.005 1.44 (1.14–1.81) 0.002
Trazodone 0.58 (0.40–0.83) 0.003 0.60 (0.42–0.85) 0.005
Maprotiline 1.61 (1.07–2.43) 0.023 1.64 (1.09–2.46) 0.018
Imipramine 1.70 (0.86–3.38) 0.129
Nortriptyline 1.41 (0.56–3.52) 0.462
Fluvoxamine 1.45 (0.94–2.24) 0.089
Hosmer & Lemeshow test 0.003 0.781
Discrimination (Area Under Curve COR) 0.749 <0.001 0.729 <0.001
aModel 1: Multivariate association of compliance with all factors (the complete model)
bModel 2: Multivariate association of compliance with all statistically significant factors
Ref.: Reference category
Serna et al. BMC Public Health  (2015) 15:1184 Page 5 of 8
Other studies have also reported problems with the
diagnosis. The Netherlands Mental Health Survey and
Incidence Study found that in around half of patients
treated with antidepressants the diagnosis was not re-
corded [13]. Furthermore, between 10 % and 15 % of
long-term continuous treatments with antidepressants
were found to be no longer necessary. Conceivably,
some patients may not have received a specific diagnosis
because of the difficulty of coding certain poorly defined
conditions in a situation in which the pressure on health
staff is intense [27].
Thirdly, very often the same psychological or pharma-
cological treatment is effective for several different men-
tal disorders [28]. One of the reasons for the limited
clinical utility of current diagnostic systems is their
extraordinary complexity and the inclusion, with each
new review, of a greater number of categories with in-
creasingly fine distinctions [26].
The most frequently prescribed drug during the early
period (years 2003–2008) was paroxetine, followed by
fluoxetine and sertraline. The most common prescrip-
tion in the second period (2008–2011) was paroxetine,
followed by escitalopram and then venlafaxine. A study
conducted in Italy between 2000 and 2011 recorded an
increase in the consumption of antidepressants and es-
pecially the group of selective serotonin reuptake inhibi-
tors (SSRIs) [29].
The increase in the prescription of venlafaxine and
escitalopram may reflect a policy of changing the active
principle due to non-response to treatment. It is esti-
mated that at least half of the people starting antidepres-
sant treatment do not respond and a third remain
depressed, despite the use of a variety of treatment strat-
egies [21]. There has also been a change in prescription
patterns on the part of physicians; a previous study re-
ported an increase in the prescription of new molecules
between 2002 and 2004 [30]. There is considerable com-
mercial pressure on doctors to prescribe these new
drugs, although this practice is not always justified by
their clinical efficacy and safety.
Another reason for the increase in prescription of
venlafaxine and escitalopram may be resistance to
treatment. According to the clinical guidelines for de-
pression, if treatment with SSRIs has proven ineffective,
it can be replaced with venlafaxine, duloxetine or mirta-
zapine, and vice versa. If after a reasonable time no sig-
nificant improvement is observed, an option would be to
prescribe tricyclic antidepressants such as imipramine at
doses of 150–300 mg/day [31].
Just over two-thirds of our patients (68.6 %) had
received 1 or 2 antidepressant drugs at different
times during the study period. The rest had con-
sumed between three and thirteen different anti-
depressant drugs.
Overall compliance was 22 %. The compliance rate
was 28 % in patients diagnosed with depression, and
21 % in those diagnosed with anxiety. The factors
associated with increased treatment compliance were
polypharmacy and a diagnosis of depressive or mixed
disorder. The low overall rate of compliance may be as-
sociated with recurrences. It is known that recurrence
risk in major depression is high; 50 % of patients have a
new episode after the first one, 70 % after two, and as
many as 90 % after three [32]. For this reason, an im-
portant question in the treatment of major depression is
how long drug treatment should be maintained after re-
covery in order to prevent recurrence. Few studies have
been specifically designed to address this issue and there
is no clear consensus in the recommendations in other
guidelines. In general, patients who abandon antidepres-
sant treatment have a higher risk of recurrence than
those who continue and, theoretically, patients with
higher risk of recurrence would be the ones that would
benefit the most from a prolonged treatment regimen
[33]. Furthermore, the more prolonged the treatment,
the smaller the difference in the risk of recurrence be-
tween treated patients and controls; that is, the benefit
of extending treatment decreases over time [34]. Adjust-
ing the duration of treatment after recovery to the type
of patient is a considerable challenge and must be evalu-
ated on a case-to-case basis.
Higher rates of compliance at older ages have been re-
ported in some studies [35] which record shorter treat-
ment periods in younger patients and in people in
situations of socio-economic deprivation. However, in
our study at multivariate level, compliance showed no
significant differences with regard to age.
Among the various drugs prescribed, the highest com-
pliance rates were observed with clomipramine, mirtaza-
pine, maprotiline, and venlafaxine, and the lowest with
paroxetine and trazodone. Other studies reported higher
compliance with treatment with venlafaxine and duloxe-
tine than with SSRIs, although this may be attributed to
differences in clinical or pharmacological profiles. Sero-
tonin reuptake inhibitors are used in first-line treatment
with antidepressants. However, norepinephrine reuptake
inhibitors are used in patients in more complex situa-
tions (i.e., recurrences or comorbidity) or in more severe
cases [36].
Among the limitations of the data collection, the pos-
sible loss of some prescriptions should be borne in mind,
because the drugs may have been dispensed over the
counter or with prescriptions made by doctors outside
the social security system. However, it has been esti-
mated that these prescriptions account for a low per-
centage of the total in the health region; therefore, given
the public health system’s universal coverage [37] the re-
sults of the survey can be considered valid. Furthermore,
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studies of this kind based on routine data bases lack in-
formation on cultural and social factors and on patients’
opinions, which also have an important bearing on the
analysis of compliance. Another limitation is the lack of
clinical information on the patients without a recorded
diagnosis justifying treatment with antidepressants, and
the absence of data regarding the severity of depression
and patient response to antidepressants. It should also
be borne in mind that we selected patients with an
initial prescription in 2003 and who were prescribed
antidepressant medication in 2008; we do not have infor-
mation regarding their continuity over the intervening
period or the number of episodes. This point should be
considered when evaluating the results.
Conclusions
In conclusion, we describe a cohort of patients who re-
ceived treatment with antidepressants during the study
period on two or more occasions. Almost half of the
patients had no recorded diagnosis; a quarter had anx-
iety disorder, and another quarter depression or mixed
anxiety-depression disorder. Approximately 1 in 4 pa-
tients complied with the treatment prescribed. The fac-
tors associated with compliance were polypharmacy and
a diagnosis of depressive or mixed disorder. Drugs asso-
ciated with increased compliance were clomipramine,
mirtazapine, maprotiline and venlafaxine, while lower
compliance was observed with paroxetine and trazodone
after adjusting for different variables.
Access to diagnostic guidelines that are better suited
to primary care would facilitate the compilation of pa-
tients’ clinical records and their treatments. Moreover, to
improve compliance a deeper understanding of effective
interventions is required, since abandonment is associated
with an increase in the number of recurrences. Further
studies are needed to define the treatment periods re-
quired in chronic or recurrent situations in the light of the
patient’s symptoms and to identify the treatment dura-
tions associated with the fewest relapses. Progress in these
areas would help to improve our approaches to these
mental illnesses which have such a high prevalence in the
population.
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